This is a plain language summary of a clinical research study called XTEND-1. The study looked into how safe and effective a medicine called efanesocto-cog alfa is for people with severe hemophilia AThis Plain Language Summary of Publication article (PLSP) from Future Rare Diseases summarises the results from a study called XTEND-1. The study measured the safety and effectiveness of a medicine, called efanesoctocog alfa, for treating Hemophilia A. Hemophilia A is a genetic condition that causes people to be more prone to bleeding.

Visit the Future Medicine using the link to read the article.

This PLSP is based on an original article called ‘Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A’ and was published in The New England Journal of Medicine.

Visit The New England Journal of Medicine using the link to read the article.